ISU researcher blown away by blood cell replication discovery  Radio Iowa

Read the rest here:
ISU researcher blown away by blood cell replication discovery - Radio Iowa

Pausing biological clock could give boost to lab-produced blood stem cells  Phys.org

More here:
Pausing biological clock could give boost to lab-produced blood stem cells - Phys.org

9-year-old gets successful bone marrow transplant  The Times of India

Read more from the original source:
9-year-old gets successful bone marrow transplant - The Times of India

Dr. Crandall: Stem Cell Treatment Heals the Heart  Newsmax

Link:
Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax

The heart is a resident tissue for hematopoietic stem and progenitor cells in zebrafish  Nature.com

Go here to see the original:
The heart is a resident tissue for hematopoietic stem and progenitor cells in zebrafish - Nature.com

ORION CORPORATION MANAGERS’ TRANSACTIONS 15 AUGUST 2024 at 15.30 EEST

Originally posted here:
Orion Corporation: Managers’ transactions – Hao Pan

ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments.

Read more from the original source:
BioCorRx Reports Business Update for the Second Quarter of 2024

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company’s common stock is expected begin trading on the Nasdaq Capital Market under the same symbol (ALGS) on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204.

See more here:
Aligos Therapeutics Announces Reverse Stock Split

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.

More:
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates...

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th.

Original post:
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

ANKARA, Turkey, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. (OTC: PRTT) ("Company") announces the appointment of a new CEO, restructuring of the Board of Directors, and looks to finalize the merger agreement with Karinca Logistics - www.karincalogistics.com.

Excerpt from:
Protect Pharmaceutical Corp. (PRTT) Announces New CEO and New Director; Moves to Finalize the Karinca Logistics Merger

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.

Original post:
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant advancements in their manufacturing process of exosomes. Exosomes, which are naturally released by cells, hold immense promise for regenerative medicine and they are at the heart of the Company’s innovative ExoPTEN product, which is being developed for the treatment of acute spinal cord injury and glaucoma.

Follow this link:
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Tevogen Bio Inc (Nasdaq: TVGN), please note that paragraph two has been updated. The corrected release follows:

Read this article:
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern,...

The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024

Originally posted here:
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers

Here is the original post:
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns

Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board

See more here:
Codexis Publishes FY2023 Sustainability Disclosures

Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

See the rest here:
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

iPSCs Manufacturing for Cell-Based Therapies: A Market Analysis of Cell Types, Therapeutic Applications, Ma...  WhaTech

Go here to see the original:
iPSCs Manufacturing for Cell-Based Therapies: A Market Analysis of Cell Types, Therapeutic Applications, Ma... - WhaTech

First Successful Paediatric Allogeneic Bone Marrow Transplant In Bengaluru; Know All About The Procedure  Onlymyhealth

Go here to see the original:
First Successful Paediatric Allogeneic Bone Marrow Transplant In Bengaluru; Know All About The Procedure - Onlymyhealth